Tight Junction Antagonists for Lung Permeability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI) are limited, as they do not effectively address the loss of endothelial barrier integrity leading to pulmonary edema and excessive lung tissue permeability.
Innovation Solution
Administration of a tight junction antagonist, such as a peptide with specific sequences like G-G-V-L-V-Q-P-G, to prevent the opening of tight junctions in lung microvascular endothelial cells, thereby reducing lung permeability and treating ALI and ARDS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If tight junction agonists (such as ZOT and ΔG) are used to open tight junctions to facilitate macromolecule transfer, then macromolecule transfer across epithelial barriers is improved, but lung permeability increases and endothelial barrier integrity is lost
Solution Approach 1:
Instead of using tight junction agonists to open tight junctions (which increases permeability), the patent applies tight junction antagonists to maintain tight junction closure. This inverted approach prevents the harmful increase in lung permeability while still allowing controlled macromolecule transfer through intact endothelial barriers.
Solution Approach 2:
The patent converts the harmful effect of increased permeability into a beneficial therapeutic effect by using tight junction antagonists to prevent pathological permeability increases. The same tight junction modulation mechanism that causes harm when overactivated is now controlled to provide therapeutic benefit in treating ALI and ARDS.
2Reliability
If supportive mechanical ventilation is used as standard care for ARDS, then respiratory failure is managed, but endothelial barrier integrity loss and pulmonary edema are not effectively treated
Solution Approach 1:
The patent introduces tight junction antagonists as an intermediary therapeutic agent that acts on the endothelial barrier to prevent permeability increases. This mediator addresses the root cause (endothelial barrier loss) rather than just managing the symptom (respiratory failure), complementing mechanical ventilation with a targeted pharmacological intervention.
Solution Approach 2:
The tight junction antagonist enables the endothelial barrier to self-regulate its own integrity by preventing pathological opening of tight junctions. The body's natural barrier function is restored and maintained through pharmacological support of the tight junction complex, allowing the endothelium to resist injurious stimuli independently.
3Object-affected harmful factors
If tight junction antagonists are administered to prevent tight junction opening, then endothelial barrier integrity is maintained and lung permeability is reduced, but the ability to facilitate macromolecule transfer is decreased
Solution Approach 1:
The patent changes the state parameter of tight junctions from 'open' to 'closed/maintained' by administering tight junction antagonists. This parameter change reduces lung permeability to pathological levels while preserving the physiological ability to transfer macromolecules through intact barriers, as the tight junctions remain functional but not pathologically activated.
Data Source
AI summary
The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.